GSK in talks to acquire cancer biotech Nuvalent for over $9 billion, FT reports
GSK is in talks to acquire cancer-focused biotech Nuvalent in a deal valued at more than $9 billion, according to the Financial Times.
Quick reaction
One tap helps tune what we surface next.
Reader discussion
Public commentsNo comments yet. Start the discussion around this signal.
Follow this signal
Get updates on this story
We will email you if this changes materially. No spam. Daily brief optional.
Map context
See this on the live map
Keep the story in context with nearby live signals, countries, and category movement.
Related coverage
More story pages
Indian economy, government finances see mounting costs from Iran war, Reuters reports
Indian economy and government finances face mounting costs from the Iran war, according to Reuters.
Indonesia's central bank unexpectedly hikes benchmark rate 25 bps in off-cycle meeting to support the rupiah.
Indonesia's central bank unexpectedly raised its benchmark interest rate by 25 basis points in an off-cycle meeting to shore up the rupiah.
Bank of Japan to discuss ending quarterly reduction in bond buying, Nikkei reports. The potential policy shift signals a move toward normalizing monetary stimulus.
Bank of Japan to discuss ending quarterly reduction in bond buying, according to Nikkei.
Nikkei: Bank of Japan to lift rates to 1.0% at June policy meeting
The Bank of Japan is expected to raise its key interest rate to 1.0% at its June policy meeting, according to Nikkei.
More live signals
Continue with the live feed.
The fastest nearby updates load from the public feed, not the enriched story endpoint.